ArticleBMC psychology2025
Association between creatinine to cystatin C ratio and the incidence of depressive symptoms among middle-aged and older adults: insight from the CHARLS study.
Article in BMC psychology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDepressive symptoms constitute a pressing public-health concern that significantly undermines the mental well-being of older adults. There is a robust association between depression and the progressive loss of muscle mass and strength that characterizes sarcopenia. However, few studies have examined the association between the creatinine-to-cystatin C ratio (CCR), a robust biomarker of sarcopenia, and depression. This study aims to investigate the relationship between CCR and the incidence of depressive symptoms (DS).
methodsWe conducted a cohort study utilizing data from Wave 1 (2011) and Wave 3 (2013) of the China Health and Retirement Longitudinal Survey (CHARLS). A total of 4,955 individuals aged 45 years and above who were free of DS at baseline were included. The CCR was calculated as serum creatinine divided by cystatin C and categorized into quartiles. The 10-item Center for Epidemiological Studies Depression Scale (CESD-10) was used to assess DS, with a cutoff score of ≥ 12 indicating DS. Multivariate logistic regression models were employed to evaluate the association between the baseline CCR and incident DS over a two-year follow-up period. A restricted cubic splines (RCS) analysis was applied to explore the dose‒response relationship, while sensitivity and subgroup analyses were performed to test the robustness of the findings.
resultsCompared to participants in the lowest quartile of CCR, those in the third and fourth quartiles had 27.9% (OR = 0.721, 95% CI: 0.570-0.913) and 29.7% (OR = 0.703, 95% CI: 0.548-0.902) lower risks of incident DS, respectively. Each one-unit increase in the CCR was associated with a 5.6% reduction in DS risk (OR = 0.944, 95% CI: 0.901-0.990). RCS analysis revealed a linear relationship between the CCR and DS risk (P for nonlinearity = 0.477). These findings remained consistent in sensitivity and stratified analyses.
conclusionThe CCR is inversely associated with the risk of incident DS over 2 years, suggesting that the CCR may serve as a useful biomarker for predicting and managing mental health in middle-aged and older adults.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.